← Back to Search

Novel Delivery System for HIV Treatment

N/A

Recruiting

Led By Albert Liu, MD, MPH

Research Sponsored by Public Health Foundation Enterprises, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 0, 9,18 months

Awards & highlights

Study Summary

This trial tests a new HIV treatment plan for trans women. It could help improve their health outcomes.

Who is the study for?

This trial is for transwomen living with HIV who are over 18, speak English, and have controlled HIV levels. They must be interested in a new injection treatment (CAB-RPV LA), receive care at certain clinics, and have a cell phone. People can't join if they can't get gluteal injections, plan to move soon, have drug-resistant HIV strains or take certain medications.Check my eligibility

What is being tested?

The study tests an integrated delivery model of CAB-RPV LA injections for transwomen with HIV. It includes patient-centered injection sites and adherence support, provider education, and improved clinic communication strategies.See study design

What are the potential side effects?

While the trial doesn't list specific side effects for CAB-RPV LA injections, common ones may include pain at the injection site, headache, feverish symptoms or fatigue. Each person's experience with side effects could vary.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 0, 9,18 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~0, 9,18 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 0, 9,18 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Acceptability of delivering CAB-RPV LA

Client Satisfaction

Feasibility of delivering CAB-RPV LA

Secondary outcome measures

Assess adherence to injections

Assess tolerability

Assess viral suppression

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Cheeky Study InterventionExperimental Treatment4 Interventions

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

ViiV HealthcareIndustry Sponsor

360 Previous Clinical Trials

468,529 Total Patients Enrolled

Lyon-Martin Community Health ServicesUNKNOWN

San Francisco Department of Public HealthOTHER_GOV

35 Previous Clinical Trials

34,301 Total Patients Enrolled

Media Library

Cheeky Study Intervention Clinical Trial Eligibility Overview. Trial Name: NCT05979714 — N/A

Human Immunodeficiency Virus Infection Research Study Groups: Cheeky Study Intervention

Human Immunodeficiency Virus Infection Clinical Trial 2023: Cheeky Study Intervention Highlights & Side Effects. Trial Name: NCT05979714 — N/A

Cheeky Study Intervention 2023 Treatment Timeline for Medical Study. Trial Name: NCT05979714 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are expected to join this experiment?

"Affirmative. Clinicaltrials.gov contains information suggesting that this study is actively recruiting participants, having first been posted on May 31st 2023 and most recently updated July 31st 2023. It requires 50 individuals to be recruited from a single medical centre for participation in the trial."

Answered by AI

Are there any vacancies available in this clinical experiment?

"Affirmative. The research posted on clinicaltrials.gov demonstrates that the trial, initially published on May 31st 2023, is still actively enrolling individuals. Approximately 50 patients must be found at a single medical centre."

Answered by AI

What objective is this clinical trial attempting to achieve?

"The primary aim of this trial, to be assessed in intervals of 0, 9 and 18 months is to quantify the acceptability of delivering CAB-RPV LA. Secondary objectives include assessing compliance with injection schedules amongst trans women receiving CAB-RPV LA treatments; measuring their viral suppression rates; as well as describing any potential resistance mutations arising from virologic failure cases."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

The Cheeky Study: A Novel Delivery System for CAB-RPV LA

Albert Liu 2023. "The Cheeky Study: A Novel Delivery System for CAB-RPV LA". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05979714.